News
Gerresheimer Aktie: 1,5-Milliarden-Deal mit Apax-Beratung
Zwölf Prozent Kurssprung an einem einzigen Handelstag – so reagierte der Markt Ende Juli…
Der Beitrag Gerresheimer Aktie: 1,5-Milliarden-Deal mit Apax-Beratung erschien zuerst auf kapitalmarktexpert
TriSalus Life Sciences Q2 Earnings Call Highlights
Key Points
- Interested in TriSalus Life Sciences, Inc.? Here are five stocks we like better.
- Revenue rose modestly to $11.4 million in Q2, up 1.7% year over year, while TriSalus reiterated its
Nutex Health Q2 Earnings Call Highlights
Key Points
- Interested in Nutex Health Inc.? Here are five stocks we like better.
- Profitability improved sharply despite lower revenue: Second-quarter revenue fell 13.6% to $210.8 million, but
Sanuwave Health Q2 Earnings Call Highlights
Key Points
- Interested in Sanuwave Health Inc.? Here are five stocks we like better.
- Second-quarter revenue fell 3% year over year to $9.7 million, as a 34% decline in UltraMIST system sales
Scholar Rock Q2 Earnings Call Highlights
Key Points
- Interested in Scholar Rock Holding Corporation? Here are five stocks we like better.
- FDA decision remains on track for Sept. 30: Scholar Rock’s resubmitted application for
EQS-Adhoc: RHÖN-KLINIKUM Aktiengesellschaft: Asklepios Kliniken GmbH & Co. KGaA übermittelt Verlangen zur Durchführung eines Squeeze-out der Minderheitsaktionäre der RHÖN-Klinikum Aktiengesellschaft
EQS-Adhoc: RHÖN-KLINIKUM Aktiengesellschaft: Asklepios Kliniken GmbH & Co. KGaA übermittelt Verlangen zur Durchführung eines Squeeze-out der Minderheitsaktionäre der RHÖN-Klinikum Aktiengesellschaft
Privia Health Group Q2 Earnings Call Highlights
Key Points
- Interested in Privia Health Group, Inc.? Here are five stocks we like better.
- Strong Q2 performance: Privia Health’s implemented providers grew 10.1%, attributed lives increased
The Pennant Group Q2 Earnings Call Highlights
Key Points
- Interested in The Pennant Group, Inc.? Here are five stocks we like better.
- Strong Q2 performance: Revenue rose 35.8% year over year to $298 million, while adjusted EBITDA increased
Praxis Precision Medicines Q2 Earnings Call Highlights
Key Points
- Interested in Praxis Precision Medicines, Inc.? Here are five stocks we like better.
- FDA reviews are progressing for ulixacaltamide and relutrigine, with no advisory committee
Omada Health Q2 Earnings Call Highlights
Omada Health (NASDAQ:OMDA) reported record second-quarter results for 2026, citing broad-based growth across its cardiometabolic programs, expanding channel partnerships and lower costs to serve
Ocugen Q2 Earnings Call Highlights
Ocugen (NASDAQ:OCGN) said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an
INmune Bio Q2 Earnings Call Highlights
Key Points
- Interested in INmune Bio, Inc.? Here are five stocks we like better.
- Regulatory and manufacturing progress: INmune Bio plans to seek conditional U.K. approval for Ebstrocel in late
Halozyme Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Halozyme Therapeutics, Inc.? Here are five stocks we like better.
- Record Q2 performance: Revenue rose 48% year over year to $481 million, while royalty revenue increased
BioMarin Pharmaceutical Q2 Earnings Call Highlights
Key Points
- Interested in BioMarin Pharmaceutical Inc.? Here are five stocks we like better.
- BioMarin’s second-quarter revenue nearly reached $1 billion, rising 20% year over year. The company
Orion Energy Targets $95M-$97M Revenue After Margin Gains at Annual Meeting
Key Points
- Interested in Orion Energy Systems, Inc.? Here are five stocks we like better.
- Fiscal 2026 results improved: Revenue rose to $86.3 million from $79.7 million, gross margin increased
Zillow Group Q2 Earnings Call Highlights
Zillow Group (NASDAQ:Z) reported second-quarter revenue growth that exceeded its outlook, led by gains in its For Sale and
EQS-News: RHÖN-KLINIKUM AG mit weiterhin stabiler Entwicklung im Halbjahr 2026
EQS-News: RHÖN-KLINIKUM AG mit weiterhin stabiler Entwicklung im Halbjahr 2026
EQS-News: Evotec und Odyssey Therapeutics starten KI-gestützte F&E-Kooperation in Autoimmun- und Entzündungserkrankungen
EQS-News: Evotec und Odyssey Therapeutics starten KI-gestützte F&E-Kooperation in Autoimmun- und Entzündungserkrankungen
Revolution Medicines Q2 Earnings Call Highlights
Key Points
- Interested in Revolution Medicines, Inc.? Here are five stocks we like better.
- Daraxonrasib moved closer to commercialization: The FDA accepted Revolution Medicines’ application for
LifeMD Q2 Earnings Call Highlights
Key Points
- Interested in LifeMD, Inc.? Here are five stocks we like better.
- Q2 profitability missed expectations: LifeMD reported $47.3 million in revenue and an adjusted EBITDA loss of about
Exelixis Q2 Earnings Call Highlights
Key Points
- Interested in Exelixis, Inc.? Here are five stocks we like better.
- Q2 revenue reached approximately $629 million, driven by $573 million in U.S. cabozantinib franchise net product
Cirrus Logic Q1 Earnings Call Highlights
Key Points
- Interested in Cirrus Logic, Inc.? Here are five stocks we like better.
- Record quarterly performance: Cirrus Logic reported fiscal Q1 revenue of $460 million, up 13% year over year
Clover Health Investments Q2 Earnings Call Highlights
Key Points
- Interested in Clover Health Investments, Corp.? Here are five stocks we like better.
- Clover Health reported strong second-quarter results: Medicare Advantage membership rose 48%
Carlsmed Q2 Earnings Call Highlights
Key Points
- Interested in Carlsmed, Inc.? Here are five stocks we like better.
- Carlsmed’s Q2 revenue rose 57% year over year to $18.9 million, driven by higher adoption of its aprevo lumbar
Insulet Q2 Earnings Call Highlights
Key Points
- Interested in Insulet Corporation? Here are five stocks we like better.
- Strong Q2 performance: Insulet reported revenue of $802 million, up 22.7% on a constant-currency basis, while